Suivi thérapeutique des médicaments (TDM)
Les données de TDM, appliquées à des outils de pharmacocinétique de population ou à des modèles pharmacocinétiques physiologiques, permettent de décrire le comportement d’un médicament au niveau de la population et de caractériser l’impact de certains facteurs (par ex. âge, sexe, poids, insuffisance rénale, co-médications) sur l’exposition d’un médicament (voir Pharmacométrie). Par ailleurs, les données de TDM en association avec des données de réponse et de toxicité permettent de définir des intervalles thérapeutiques.
Références générales sur le TDM
Suivi thérapeutique des médicaments (I) : les principes
N. Widmer, D. Werner, E. Grouzmann, C.B Chin, O. Marchetti, A. Fayat, C. Csajka, L.A. Decosterd, T. Buclin
In Revue médicale suisse, N° 165, 16 juillet 2008, p. 1644-1648
Suivi thérapeutique des médicaments (II) : la pratique clinique
N. Widmer, C. Csajka, D. Werner, E. Grouzmann, L.A. Decosterd, B.E Chin, J. Biollaz , T. Buclin
In Revue médicale suisse, N° 165, 16 juillet 2008, p. 1649-1650
Recherche en relation avec le TDM issue de notre service
Population pharmacokinetic analysis of doravirine in real-world people with HIV.
Thoueille P, Delarive L, Cavassini M, Buclin T, Decosterd LA, Marzolini C, Girardin FR, Guidi M, Swiss HIV Cohort Study
Br J Clin Pharmacol. 2024 Apr;90(4):1058-1065
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data.
Berton M, Bettonte S, Stader F, Decosterd L, Tarr PE, Livio F, Cavassini M, Braun DL, Kusejko K, Hachfeld A, Bernasconi E, Calmy A, Schmid P, Battegay M, Marzolini C, Swiss HIV Cohort Study
Clin Infect Dis. 2024 Jan 25;78(1):98-110
Guidance for the Interpretation of Long-Acting Cabotegravir and Rilpivirine Concentrations Based on Real-World Therapeutic Drug Monitoring Data and Documented Failures.
Thoueille P, Cavassini M, Guidi M, Buclin T, Girardin FR, Decosterd LA, Marzolini C
Open Forum Infect Dis. 2024 Feb;11(2):ofae023
Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.
Thoueille P, Saldanha SA, Schaller F, Choong E, Munting A, Cavassini M, Braun D, Günthard HF, Kusejko K, Surial B, Furrer H, Rauch A, Rougemont M, Ustero P, Calmy A, Stöckle M, Marzolini C, Di Benedetto C, Bernasconi E, Schmid P, Piso RJ, Andre P, Girardin FR, Guidi M, Buclin T, Decosterd LA, Swiss HIV Cohort Study
Lancet Reg Health Eur. 2024 Jan;36:100793
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
Thoueille P, Delfraysse M, Andre P, Buclin T, Decosterd LA, Fedeli C, Ustero P, Calmy A, Guidi M, Swiss HIV Cohort Study
BMC Pharmacol Toxicol. 2023 Sep 27;24(1):47
Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective.
Briki M, André P, Thoma Y, Widmer N, Wagner AD, Decosterd LA, Buclin T, Guidi M, Carrara S
Pharmaceutics. 2023 Apr 19;15(4)
Valproate in status epilepticus: Correlation between loading dose, serum levels, and clinical response.
Vijiala S, André P, Buclin T, Decosterd LA, Rossetti AO, Novy J
Eur J Neurol. 2022 Sep;29(9):2607-2611
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Thoueille P, Alves Saldanha S, Schaller F, Munting A, Cavassini M, Braun D, Günthard HF, Kusejko K, Surial B, Furrer H, Rauch A, Ustero P, Calmy A, Stoeckle M, Battegay M, Marzolini C, Andre P, Guidi M, Buclin T, Decosterd LA, On Behalf Of The Swiss Hiv Cohort Study
Pharmaceutics. 2022 Jul 29;14(8)
Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.
Suttels V, André P, Thoma Y, Veuve F, Decosterd L, Guery B, Buclin T
JAC Antimicrob Resist. 2022 Apr;4(2):dlac043
Ensuring Sufficient Trough Plasma Concentrations for Broad-Spectrum Beta-Lactam Antibiotics in Children With Malignancies: Beware of Augmented Renal Clearance!
André P, Diezi L, Dao K, Crisinel PA, Rothuizen LE, Chtioui H, Decosterd LA, Diezi M, Asner S, Buclin T
Front Pediatr. 2021;9:768438
Therapeutic drug monitoring of newer generation antiseizure medications at the point of treatment failure.
Fluckiger P, Aícua-Rapún I, André P, Rossetti AO, Decosterd LA, Buclin T, Novy J
Seizure. 2022 Jan;94:66-69
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P, Guidi M, Alves Saldanha S, Cavassini M, Stoeckle M, Buclin T, Marzolini C, Decosterd LA, Csajka C
Eur J Clin Pharmacol. 2021 Jul;77(7):979-987
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.
Stader F, Courlet P, Decosterd LA, Battegay M, Marzolini C
Clin Pharmacol Ther. 2021 Apr;109(4):1025-1029
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K, Guidi M, André P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C
Pharmacol Res. 2020 Apr;154:104278
The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib.
Buclin T, Thoma Y, Widmer N, André P, Guidi M, Csajka C, Decosterd LA
Front Pharmacol. 2020;11:177
Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
Cardoso E, Guidi M, Blanchet B, Schneider MP, Decosterd LA, Buclin T, Csajka C, Widmer N
Ther Drug Monit. 2020 Feb;42(1):33-44
Therapeutic Drug Monitoring of Newer Antiepileptic Drugs: A Randomized Trial for Dosage Adjustment.
Aícua-Rapún I, André P, Rossetti AO, Ryvlin P, Hottinger AF, Decosterd LA, Buclin T, Novy J
Ann Neurol. 2020 Jan;87(1):22-29
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C, Aouri M, Courlet P, Guidi M, Braun DL, Günthard HF, Piso RJ, Cavassini M, Buclin T, Decosterd LA, Csajka C, Swiss HIV Cohort Study
J Antimicrob Chemother. 2019 Sep 1;74(9):2690-2697
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, Marzolini C, Eap CB, Decosterd LA, Csajka C, Swiss HIV Cohort Study
Br J Clin Pharmacol. 2019 Sep;85(9):2022-2032
Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.
Leuppi-Taegtmeyer AB, Decosterd L, Osthoff M, Mueller NJ, Buclin T, Corti N
Antimicrob Agents Chemother. 2019 Feb;63(2)
Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical response.
Aicua-Rapun I, André P, Rossetti AO, Decosterd LA, Buclin T, Novy J
Epilepsy Res. 2019 Jan;149:88-91
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M, Barcelo C, Guidi M, Rotger M, Cavassini M, Hizrel C, Buclin T, Decosterd LA, Csajka C, Swiss HIV Cohort Study
Antimicrob Agents Chemother. 2017 Jan;61(1)
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Fuchs A, Rotzinger A, Cavassini M, Bugnon O, Buclin T, Schneider MP, Csajka C
Ther Drug Monit. 2016 Aug;38(4):506-15
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C, Gaspar F, Aouri M, Panchaud A, Rotger M, Guidi M, Cavassini M, Buclin T, Decosterd LA, Csajka C, Swiss HIV Cohort Study
J Antimicrob Chemother. 2016 Jul;71(7):1933-42
Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E, Buclin T, Guidi M, Quoix E, Gourieux B, Decosterd LA, Gairard-Dory AC, Ubeaud-Séquier G, Widmer N
Ther Drug Monit. 2015 Feb;37(1):2-21
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA, Widmer N, Zaman K, Cardoso E, Buclin T, Csajka C
Biomark Med. 2015;9(9):887-93
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, Leoncini-Franscini L, Baerlocher GM, Duchosal MA, Csajka C, Buclin T
Cancer Chemother Pharmacol. 2014 Dec;74(6):1307-19
Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.
Fuchs A, Guidi M, Giannoni E, Werner D, Buclin T, Widmer N, Csajka C
Br J Clin Pharmacol. 2014 Nov;78(5):1090-101
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M, Lubomirov R, Fayet-Mello A, Aouri M, Rotger M, Buclin T, Widmer N, Gatri M, Ledergerber B, Rentsch K, Cavassini M, Panchaud A, Guidi M, Telenti A, Décosterd LA, Csajka C, Swiss HIV Cohort Study
J Antimicrob Chemother. 2014 Sep;69(9):2489-98
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V, Bouchet S, Widmer N, Schuld P, Decosterd LA, Buclin T, Mahon FX, Csajka C, Molimard M
Leuk Res. 2014 Jul;38(7):764-72
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A, Widmer N, Guidi M, Montemurro M, Leyvraz S, Buclin T, Eap CB, Decosterd LA, Csajka C
Br J Clin Pharmacol. 2013 Apr;75(4):1007-18
Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes.
Gotta V, Buclin T, Csajka C, Widmer N
Ther Drug Monit. 2013 Apr;35(2):150-67
Benchmarking therapeutic drug monitoring software: a review of available computer tools.
Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N
Clin Pharmacokinet. 2013 Jan;52(1):9-22
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O
Clin Infect Dis. 2012 Aug;55(3):381-90
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HF, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, Csajka C, Swiss HIV Cohort Study Group
Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, Csajka C, Buclin T
Clin Pharmacokinet. 2012 Mar 1;51(3):187-201
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M, Arab-Alameddine M, Rotger M, Aouri M, Telenti A, Decosterd LA, Buclin T, Csajka C, Swiss HIV Cohort Study
Chimia (Aarau). 2012;66(5):291-5
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T
Antimicrob Agents Chemother. 2009 Jul;53(7):3017-23
Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.
Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T
Clin Pharmacokinet. 2009;48(6):399-418
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J, Buclin T
Br J Cancer. 2008 May 20;98(10):1633-40
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O
Clin Infect Dis. 2008 Jan 15;46(2):201-11
Rue du Bugnon 17
CHUV, Centre hospitalier universitaire vaudois
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 4260
Rue du Bugnon 17
CHUV, Centre hospitalier universitaire vaudois
CH-1011 Lausanne, Vaud, Suisse
+41 21 314 4260